Clinical Significance of MMP-12 Expression in Non-Small Cell Lung Cancer: Report of 38 Cases

Pan Hong,Liu Ming,Zhang Xiaoli,Zhang Xue,Huang Junfu,Wang Jue,Liu Chunjiang,Shuai Weizheng,Zhang Kejun,Fu Weiling

DOI: https://doi.org/10.16016/j.1000-5404.2010.02.028

2010-01-01

Abstract:Objective To investigate the expression and clinical significance of matrix metalloproteinase-12 (MMP-12) in non-small cell lung cancer (NSCLC). Methods Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect MMP-12 mRNA expressions in 38 NSCLC the tumor tissues, including 12 samples of stage Ⅰ and 26 of stage Ⅱ and Ⅲ, and the matched normal lung tissues. Western blotting was used to measure the protein expression of MMP-12 in some tissue samples. Clinicopathological data were collected, and the relationship of MMP-12 mRNA and MMP-12 protein expression were analyzed with the clinicopathological characteristics of NSCLC. Results There was no expression of MMP-12 in 38 matched normal lung tissue, and MMP-12 mRNA was expressed in the NSCLC at stage Ⅰ (0.551±0.140), and at stage Ⅱ and Ⅲ tumor tissues (1.082±0.424) with significant difference (P=0.001), MMP-12 protein was not found in normal lung tissues, but expressed mild in the cancer tissue at stage Ⅰ, and highly in the tissues at stage Ⅱ and Ⅲ. Conclusion MMP-12 is highly expressed in NSCLC at stage of Ⅱ and Ⅲ, and significantly correlated with lymphatic node metastasis. The abnormal expression of MMP-12 in gene transcription may play an important role in the tumorogenesis and development of NSCLC.